Alector - ALEC Stock Forecast, Price & News

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Mizuho assumed coverage on shares of Alector in a research report on Wednesday, July 6th. They issued a "buy" rating and a $15.00 price target for the company. Barclays reduced their target price on shares of Alector from $42.00 to $14.00 in a report on Wednesday, May 11th. TheStreet raised shares of Alector from a "d" rating to a "c-" rating in a report on Friday, August 5th. Citigroup reduced their target price on shares of Alector from $34.00 to $19.00 and set a "buy" rating for the company in a report on Monday, July 11th. Finally, The Goldman Sachs Group reduced their target price on shares of Alector from $9.00 to $6.00 and set a "sell" rating for the company in a report on Tuesday, May 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $20.86.

Alector Stock Down 2.3 %

Shares of Alector stock opened at $12.89 on Tuesday. The company's 50-day simple moving average is $10.68 and its 200-day simple moving average is $12.01. Alector has a 52-week low of $7.50 and a 52-week high of $29.30. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of 33.05 and a beta of 1.08.

Alector (NASDAQ:ALEC - Get Rating) last issued its earnings results on Thursday, August 4th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.59. Alector had a net margin of 12.06% and a return on equity of 12.16%. Equities research analysts anticipate that Alector will post -1.3 EPS for the current year.